Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma
Open accessThe DOI matches its Crossref record.
Abstract
The development of BRAF-I resistance in BRAFV600E \nmelanoma underlies the need to develop strategies to \ncounteract this resistance. It has been shown that administration of heat shock protein 90 (HSP90) inhibitors can \ncounteract multiple mechanisms which drive BRAF-I \nresistance by reactivation of MAPK and activation of \nPI3K/AKT pathway. However the clinical application of \nthis strategy is hampered the high toxicity associated \nwith administration of currently available HSP90 inhibitors. To overcome this limitation we have developed a \nnovel monoclonal antibody (mAb), named W9, which \nrecognizes an extracellular epitope of glucose regulated \nprotein of 94 kDa (Grp94), a member of the HSP90 \nfamily. The mAb W9 defined Grp94-epitope is selectively \nexpressed on malignant cells but is not detectable on \nnormal cells. Therefore targeting Grp94-epitope by mAb \nW9 is expected to cause limited if any side effects. The \nmAb W9 was found to increase and restore the sensitivity to BRAF-I of BRAFV600E melanoma cells including \ncells which have acquired BRAF-I resistance because of \nPDGFRa upregulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
Hoter, A., El-Sabban, M. E., & Naim, H. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092560 · Cited by 693
“For instance, the monoclonal antibody (W9 mAb) was recently used and precisely targets the extracellular epitope of gp96 which is barely found in normal cells [232].”
MethodSkin tissue engineering: wound healing based on stem-cell-based therapeutic strategies
Nourian Dehkordi, A., Mirahmadi Babaheydari, F., Chehelgerdi, M., & Raeisi Dehkordi, S. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1212-2 · Cited by 533
Han, C., & Hong, Y.-C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-015-0617-2 · Cited by 132
Sun, T., Yang, W., Toprani, S. M., Guo, W., He, L., DeLeo, A. B., Ferrone, S., Zhang, G., Wang, E., Lin, Z., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-019-0507-3 · Cited by 74
Self-citationKim, M.-J., Choi, B., Kim, J. Y., Min, Y., Kwon, D. H., Son, J., Lee, J. S., Lee, J. S., Chun, E., & Lee, K.-Y. (2022) · Translational Oncology · doi:10.1016/j.tranon.2021.101250 · Cited by 28
Metadata
- Authors
- Sabbatino, F., Favoino, E., Wang, Y., Wang, X., Villani, V, Cai, L., Yang, L., Ferrone, S., & Ferrone, C.
- Venue
- Journal of Translational Medicine
- Published
- 2015-01-15
- Volume
- 13
- Issue
- S1
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W1715905369
- Cited by
- 48
- References
- 0
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma. https://app.cochat.ai/papers/10.1186/1479-5876-13-s1-k12
- The paper
- Sabbatino, F., Favoino, E., Wang, Y., Wang, X., Villani, V, Cai, L., Yang, L., Ferrone, S., & Ferrone, C. (2015). Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAFV600E melanoma. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-13-s1-k12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.